Citations for
The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.
Lan X, Xiao F, Ding Q, Liu J, Liu J, Li J, Zhang J, Tian DA.
J Mol Histol 45(6):689-96. doi: 10.1007/s10735-014-9593-0. Epub 2014 Aug 24. 2014
Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease.
Schroepf S, Kappler R, Brand S, Prell C, Lohse P, Glas J, Hoster E, Helmbrecht J, Ballauff A, Berger M, von Schweinitz D, Koletzko S, Lacher M.
Inflamm Bowel Dis nflamm Bowel Dis. 2010 Apr 30. [Epub ahead of print]PMID: 20848514 2010
CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
Rosenblum JM, Shimoda N, Schenk AD, Zhang H, Kish DD, Keslar K, Farber JM, Fairchild RL.
J Immunol 184(7):3450-60. Epub 2010 Mar 1.PMID: 20194716 2010
G-protein-coupled receptor independent, immunomodulatory properties of chemokine CXCL9.
Gong JH, Nicholls EF, Elliott MR, Brown KL, Hokamp K, Roche FM, Cheung CY, Falsafi R, Brinkman FS, Bowdish DM, Hancock RE.
Cell Immunol 261(2):105-13. Epub 2009 Dec 3.PMID: 20038462 2010
Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
Trotta T, Costantini S, Colonna G.
Mol Immunol 47(2-3):332-9. Epub 2009 Oct 1.PMID: 19800124 2009
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.
Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C.
Gastroenterology 137(1):309-19, 319.e1-3. Epub 2009 Apr 1.PMID: 19344719 2009
Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice.
Caso G, Barry C, Patejunas G.
J Hematol Oncol 2:7.PMID: 19200397 2009
CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease.
Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR.
J Am Soc Nephrol 19(6):1177-89. Epub 2008 Mar 12.PMID: 18337479 2008
The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma.
Linge HM, Collin M, Giwercman A, Malm J, Bjartell A, Egesten A.
J Interferon Cytokine Res 28(3):191-6.PMID: 18338951 2008
Association of a CXCL9 polymorphism with pediatric Crohn's disease.
Lacher M, Kappler R, Berkholz S, Baurecht H, von Schweinitz D, Koletzko S.
Biochem Biophys Res Commun 363(3):701-7. Epub 2007 Sep 18. 2007
Close resemblance between chemokine receptor expression profiles of lymphoproliferative disease of granular lymphocytes and their normal counterparts in association with elevated serum concentrations of IP-10 and MIG.
Momose K, Makishima H, Ito T, Nakazawa H, Shimodaira S, Kiyosawa K, Ishida F.
Int J Hematol 86(2):174-9.PMID: 17875534 2007
12CXCR3, CXCl9, CXCL10, CXCL11
Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
Xanthou G, Williams TJ, Pease JE.
Eur J Immunol 33(10):2927-36. 2003
High-resolution mapping of the human 4q21 and the mouse 5E3 SCYB chemokine cluster by fiber-fluorescence in situ hybridization
Erdel M, Theurl M, Meyer M, Duba HC, Utermann G, Werner-Felmayer G.
Immunogenetics 53(7):611-5. 2001
Localization of the gene for the human MIG cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine mini-cluster.
Lee HH, et al.
Cytogenet Cell Genet 74 : 255-258. 1996